Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.20
-0.13 (-2.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $424.1M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.9B
P/E
23.8x
↑EV/EBITDA
14.0x
↑ROE
14.4%
↑Gross Margin
58.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.0%
FCF CAGR
—
FCF margin
14.0%
FCF / Net income
0.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.57B · net income $398.8M · FCF $219.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.57B | $1.57B | $1.53B | $1.81B | $2.30B |
| Net Income | $398.8M | $398.8M | $356.0M | $181.9M | $323.4M |
| EBITDA | $516.5M | $516.5M | $462.7M | $278.7M | $430.3M |
| EPS | 0.32 | 0.32 | 0.28 | 0.14 | 0.25 |
| Gross Margin | 58.4% | 58.4% | 54.9% | 43.3% | 38.6% |
| Operating Margin | 21.2% | 21.2% | 19.3% | 9.2% | 10.8% |
| Net Margin | 25.4% | 25.4% | 23.3% | 10.0% | 14.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 |
| Current Ratio | 7.30 | 7.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $219.8M | $219.8M | $424.1M | $433.0M | $-142.5M |
| Returns | |||||
| ROE | 14.4% | 14.4% | 14.1% | 7.4% | 13.2% |
| Valuation | |||||
| P/E | 23.85 | 23.85 | 21.46 | 42.36 | 26.52 |
| EV/EBITDA | 14.01 | 14.01 | 15.61 | 25.77 | 19.21 |
| P/B | 2.79 | 2.79 | 3.04 | 3.14 | 3.50 |
| Growth & Yield | |||||
| Revenue Growth | 3.0% | 3.0% | -15.9% | -21.2% | — |
| EPS Growth | 14.3% | 14.3% | 100.0% | -44.0% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
19.8%
EPS terminal req.
$0.55
Spread vs growth
-5.5%
5Y implied EPS CAGR
15.8%
EPS terminal req.
$0.67
Spread vs growth
-1.5%
10Y implied EPS CAGR
12.9%
EPS terminal req.
$1.07
Spread vs growth
1.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.3%
Start / end P/E
21.9x → 19.4x
EPS bridge
0.28 → 0.32
Residual
-1.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.